Citations 1
Substrate Characterization and Outcomes of Ventricular Tachycardia Ablation in Amyloid Cardiomyopathy: A Multicenter Study
Compagnucci, Paolo , Russo, Antonio Dello, Gasperetti, Alessio , Schiavone, Marco , Sehrawat, Ojasav , Hasegawa, Kanae , Liang, Jackson J. , Fazia, Vincenzo Mirco La , Bogun, Frank , Stevenson, William G. , Siontis, Konstantinos C. , Tandri, Harikrishna , Natale, Andrea , Mohanty, Sanghamitra , Liang, Jackson , Kapa, Suraj , La Fazia, Vincenzo Mirco , Stevenson, William , Tondo, Claudio , Siontis, Konstantinos C , Santangeli, Pasquale , Natale, Andrea , Casella, Michela , Compagnucci, Paolo , Russo, Antonio Dello, Kapa, Suraj , Tondo, Claudio , Santangeli, Pasquale
Circulation: Arrhythmia and Electrophysiology | August 22, 2024 | Volume: 17 | Issue: 9 | Pages: No page available
BACKGROUND: Sustained ventricular tachycardia (VT) in cardiac amyloidosis is uncommon, and the substrate and outcomes of catheter ablation are not defined. METHODS: We included 22 consecutive patients (mean age, 68±10 years; male sex, 91%) with cardiac amyloidosis (ATTR [transthyretin], n=16; light chain, n=6) undergoing catheter ablation for VT/ventricular fibrillation (VF) between 2013 and 2023 in a retrospective, observational, international study. The primary efficacy outcome was recurrent VT/VF during follow-up, while the primary safety end point included major procedure-related adverse events. RESULTS: The indication for ablation was drug-refractory VT in 17 patients (77%), and premature ventricular complex–initiated polymorphic VT/VF in 5 patients (23%). Catheter ablation was performed using endocardial (n=17.77%) or endo-epicardial approaches (n=5.23%). Complete endocardial electroanatomical voltage maps of the left and right ventricles were obtained in 17 (77%) and 10 (45%) patients, respectively. Each patient had evidence of low-voltage areas, most commonly involving the interventricular septum (n=16); late potentials were recorded in 16 patients (73%). A median of 1 (1–2) VT was inducible per patient; 12 of the 26 mappable VTs (46%) originated from the interventricular septum. Complete procedural success was achieved in 16 patients (73%), with 4 (18%) major procedure-related adverse events. After a median follow-up of 32 (14–42) months, sustained VT/VF recurrence was observed in 9 patients (41%); survival free from VT/VF recurrence was 56% (95% CI, 36%–86%) at 36-month follow-up, and most patients remained on antiarrhythmic drugs. A significant reduction in per patient implantable cardioverter defibrillator therapies was noted in the 6-month period after ablation (before: 6 [4–9] versus after: 0 [0–0]; P <0.001). In multivariable analysis, complete procedural success was associated with reduced risk of recurrent VT/VF (hazard ratio, 0.002; P =0.034). CONCLUSIONS: Catheter ablation can achieve control of recurrent VT/VF in more than half of patients with cardiac amyloidosis, and the reduction in VT/VF burden post-ablation may be relevant for quality of life. Septal substrate and risk of procedure-related complications challenge successful management of patients with cardiac amyloidosis and VT/VF.